# RadNet, Inc. (RDNT) Informational only - not investment advice. CIK: 0000790526 SIC: 8071 Services-Medical Laboratories SIC breadcrumb: [Services](/division/I/) > [SIC Major Group 80](/major-group/80/) > [SIC 8071 Services-Medical Laboratories](/industry/8071/) Latest 10-K filed: 2026-03-02 SEC page: https://www.sec.gov/edgar/browse/?CIK=790526 Filing source: https://www.sec.gov/Archives/edgar/data/790526/000162828026013337/rdnt-20251231.htm ## At a glance FY2025 · period end 2025-12-31 · filed 2026-03-02 · accession 0001628280-26-013337 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000790526.json | Metric | Value | FY | Provenance | | --- | ---: | ---: | --- | | Revenue | 2,040,210,000 USD | 2025 | verified | | Net income | -18,652,000 USD | 2025 | verified | | Assets | 3,758,563,000 USD | 2025 | verified | | Net margin | -0.91% | 2025 | computed | | Operating margin | 3.04% | 2025 | computed | | Revenue YoY | +11.51% | 2025 | computed | | ROE | -1.71% | 2025 | computed | Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity. No market price, no rating, no forecast on this site. Not investment advice. ### Peer percentile fingerprint | Ratio | RDNT | Peer median | Percentile | N | | --- | ---: | ---: | ---: | ---: | | Net margin | -0.9% | -7.7% | 73 | 12 | | Operating margin | 3.0% | -10.3% | 64 | 12 | | Revenue growth | 11.5% | 13.8% | 33 | 13 | | ROE | -1.7% | -7.0% | 75 | 13 | | ROA | -0.5% | -5.6% | 77 | 14 | | Liabilities / equity | 2.20 | 0.40 | 83 | 13 | | Current ratio | 1.76 | 5.05 | 23 | 14 | Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 8071 Services-Medical Laboratories, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking. ## Selected Fundamentals | Metric | Value | Unit | FY | Filed | | --- | ---: | --- | ---: | --- | | Revenue | 2040210000 | USD | 2025 | 2026-03-02 | | Net income | -18652000 | USD | 2025 | 2026-03-02 | | Assets | 3758563000 | USD | 2025 | 2026-03-02 | ## Financials Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-02. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000790526.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts. | Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | | | 975,146,000 | 1,154,179,000 | 1,071,840,000 | 1,315,077,000 | 1,430,061,000 | 1,616,630,000 | 1,829,664,000 | 2,040,210,000 | | Net income | 7,230,000 | 53,000 | 32,243,000 | 14,756,000 | -14,840,000 | 24,727,000 | 10,650,000 | 3,044,000 | 2,793,000 | -18,652,000 | | Operating income | 38,480,000 | 50,050,000 | 30,886,000 | 69,878,000 | 35,684,000 | 82,554,000 | 46,363,000 | 98,697,000 | 104,621,000 | 61,992,000 | | Diluted EPS | 0.15 | 0.00 | 0.66 | 0.29 | -0.29 | 0.46 | 0.17 | 0.05 | 0.04 | -0.25 | | Operating cash flow | 91,641,000 | 142,225,000 | 116,754,000 | 104,322,000 | 233,759,000 | 149,491,000 | 146,417,000 | 220,863,000 | 233,023,000 | 298,820,000 | | Assets | 849,476,000 | 868,979,000 | 1,109,330,000 | 1,646,986,000 | 1,786,657,000 | 2,058,474,000 | 2,433,907,000 | 2,690,473,000 | 3,286,690,000 | 3,758,563,000 | | Liabilities | 797,423,000 | 799,054,000 | 909,077,000 | 1,413,847,000 | 1,528,354,000 | 1,712,317,000 | 1,942,455,000 | 1,877,114,000 | 2,153,280,000 | 2,402,677,000 | | Stockholders' equity | 52,053,000 | 61,560,000 | 127,184,000 | 151,685,000 | 165,743,000 | 228,904,000 | 332,995,000 | 630,695,000 | 902,308,000 | 1,089,890,000 | | Cash and cash equivalents | 20,638,000 | 51,322,000 | 10,389,000 | 40,165,000 | 102,018,000 | 134,606,000 | 127,834,000 | 342,570,000 | 740,020,000 | 767,215,000 | ### Ratios ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported. | Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Net margin | | | 3.31% | 1.28% | -1.38% | 1.88% | 0.74% | 0.19% | 0.15% | -0.91% | | Operating margin | | | 3.17% | 6.05% | 3.33% | 6.28% | 3.24% | 6.11% | 5.72% | 3.04% | | Return on equity | 13.89% | 0.09% | 25.35% | 9.73% | -8.95% | 10.80% | 3.20% | 0.48% | 0.31% | -1.71% | | Return on assets | 0.85% | 0.01% | 2.91% | 0.90% | -0.83% | 1.20% | 0.44% | 0.11% | 0.08% | -0.50% | | Liabilities / equity | 15.32 | 12.98 | 7.15 | 9.32 | 9.22 | 7.48 | 5.83 | 2.98 | 2.39 | 2.20 | | Current ratio | 1.40 | 1.23 | 0.87 | 0.74 | 0.68 | 0.87 | 0.79 | 1.32 | 2.12 | 1.76 | ## As-reported value updates 4 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period. Ledger: /company/RDNT/revisions/ ## Quarterly Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-10. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000790526.json. Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived. | Quarter | End date | Revenue | Net income | Diluted EPS | Method | | --- | --- | ---: | ---: | ---: | --- | | 2022-Q3 | 2022-09-30 | | | 0.01 | reported discrete quarter | | 2023-Q1 | 2023-03-31 | | | -0.36 | reported discrete quarter | | 2023-Q2 | 2023-06-30 | | | 0.12 | reported discrete quarter | | 2023-Q3 | 2023-09-30 | 401,968,000 | 17,540,000 | 0.25 | reported discrete quarter | | 2023-Q4 | 2023-12-31 | 420,383,000 | -1,860,000 | | derived Q4 = FY annual - nine-month YTD | | 2024-Q1 | 2024-03-31 | 431,707,000 | -2,779,000 | -0.04 | reported discrete quarter | | 2024-Q2 | 2024-06-30 | 459,714,000 | -2,982,000 | -0.04 | reported discrete quarter | | 2024-Q3 | 2024-09-30 | 461,142,000 | 3,209,000 | 0.04 | reported discrete quarter | | 2024-Q4 | 2024-12-31 | 477,101,000 | 5,345,000 | | derived Q4 = FY annual - nine-month YTD | | 2025-Q1 | 2025-03-31 | 471,399,000 | -37,926,000 | -0.51 | reported discrete quarter | | 2025-Q2 | 2025-06-30 | 498,230,000 | 14,454,000 | 0.19 | reported discrete quarter | | 2025-Q3 | 2025-09-30 | 522,869,000 | 5,417,000 | 0.07 | reported discrete quarter | | 2025-Q4 | 2025-12-31 | 547,712,000 | -597,000 | | derived Q4 = FY annual - nine-month YTD | | 2026-Q1 | 2026-03-31 | 575,631,000 | -33,466,000 | -0.43 | reported discrete quarter | | 2026-Q2 | 2026-06-30 | 622,720,000 | 7,530,000 | 0.10 | reported discrete quarter | ## Filed narrative (10-K & 10-Q) ## Business Verbatim Item 1 Business section from RDNT's latest 10-K: [/company/RDNT/business/](/company/RDNT/business/). ## Risk Factors Verbatim Item 1A Risk Factors from RDNT's latest 10-K: [/company/RDNT/risk-factors/](/company/RDNT/risk-factors/). ## Latest quarter (10-Q) Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/790526/000162828026055338/rdnt-20260630.htm Extracted from a substantive MD&A body after the formal Item 2 span was a TOC or reference stub. Confidence: high Filing date: 2026-08-10 Report date: 2026-06-30 Overview Our operations comprise two segments for financial reporting purposes for this reporting period, Imaging Centers and Digital Health. 33 Table of Contents Within our Imaging Centers segment, we are a national provider of diagnostic imaging services in the United States. As of June 30, 2026, we operated directly, or indirectly through joint ventures with hospitals and health system partners, 442 centers located in Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas, and Virginia. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. Internationally, our subsidiary The HLH Imaging Group Limited (“HLH Imaging”), provides teleradiology services for remote interpretation of images on behalf of providers within the framework of the United Kingdom's National Health Service. We established a Digital Health business segment during our 2024 fiscal year under the umbrella brand “DeepHealth.” The Digital Health segment combines our former Artificial Intelligence (“AI”) business with our workflow solutions, including those previously marketed under the eRAD brand. This includes providing AI-powered health informatics aimed at empowering breakthroughs in care through imaging. It leverages advanced AI to improve operational efficiency and clinical outcomes in breast, chest, musculoskeletal, neuro, prostate and thyroid health. At the heart of the portfolio is a cloud-native operating system—DeepHealth OS—that unifies data across clinical and operational workflows. By integrating AI, workflow orchestration and data management into a single operating system, the Digital Health segment enables health systems to better automate radiology, guide patient journeys, stage-shift disease and advance acute care. The Digital Health segment provides these solutions to RadNet and to 2,983 customers in the United States and internationally. The Digital Health segment’s solutions have been clinically validated and are already delivering measurable impact at scale. Our technology is deployed worldwide, including at thousands of screening sites in the United States and Europe, and is the most widely used solution for lung cancer screening in the United Kingdom. Clinical outcomes demonstrate strong performance, including a 21% increase in cancer detection rates in breast screening. Our end-to-end solutions are widely adopted in real-world settings, including by RadNet and external customers, and support more than 24 million scans worldwide. As part of our continued strategic expansion in Digital Health, in 2025 we completed three acquisitions: iCAD, Inc. (“iCAD”), a provider of AI-powered breast health solutions; See-Mode Technologies Pte. Ltd. (“See-Mode”), a medical technology company focused on enhancing ultrasound-based diagnostics through artificial intelligence; and CIMAR (UK) Limited (“CIMAR”), a cloud-native provider of image-exchange solutions. In the first quarter of 2026, we acquired Gleamer SAS (“Gleamer”), a radiology AI company with a portfolio of AI solutions across X-ray, magnetic resonance imaging (“MRI”), computed tomography (“CT”), and mammography. iCAD and See-Mode are already fully integrated into the Digital Health segment, with See-Mode’s technology deployed at 345 RadNet imaging services centers to improve the efficiency of thyroid ultrasound exams across the network. The CIMAR integration has also been completed, including the expansion of solution deployment for HLH Imaging, RadNet’s subsidiary in the United Kingdom. We expect to complete the integration of Gleamer in the third quarter of 2026. Gleamer products have already been deployed at RadNet imaging centers in California, Arizona, Maryland, New York and Florida, and we expect them to be rolled out across most RadNet centers by the end of 2026. For further financial information about these segments, see Note 5, Segment Reporting, in the notes accompanying our financial statements included in this report. Recent Developments The following table presents the total number of imaging centers in operation, including both consolidated and non-consolidated centers, and our consolidated revenues for the six months ended June 30, 2026 and 2025: [[GREPCENT_TABLE]] [["","Six Months Ended June 30,"],["","2026","","2025"],["Centers in operation","442","","405"],["Net consolidated revenues (millions)","$","1,198","","","$","970"]] [[/GREPCENT_TABLE]] Our imaging services include MRI, CT, positron emission tomography (“PET”), nuclear medicine, mammography, ultrasound, X-ray, fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a key point of differentiation from our competitors. The multi-modality offering provides a “one-stop” solution for our customers and referral sources. It also diversifies our revenue base, and reduces our exposure to changes in reimbursement rates for certain imaging modalities. Our revenue is derived from a diverse mix of payors, including private payors and commercial insurance companies, managed care capitated payors, and government payors, such as Medicare and Medicaid. We believe our payor diversity mitigates our exposure to possible unfavorable reimbursement trends within any one payor class. Our total service fee revenue, 34 Table of Contents net of contractual allowances and discounts, and implicit price concessions for the three and six months ended June 30, 2026 and 2025 received from our various payors is summarized in the following table (in thousands): [[GREPCENT_TABLE]] [["In Thousands","Three Months Ended June 30,","","Six Months Ended June 30,"],["2026","","2025","","2026","","2025"],["Commercial insurance","$","339,401","","","$","278,902","","","$","655,367","","","$","541,410"],["Medicare","150,821","","","116,331","","","287,923","","","224,499"],["Medicaid","14,452","","","12,597","","","28,468","","","24,283"],["Workers' compensation/personal injury","13,533","","","10,642","","","25,830","","","21,114"],["Other payors","36,831","","","29,394","","","70,383","","","57,087"],["Management fee revenue","7,858","","","6,688","","","15,339","","","12,967"],["Other revenue","29,693","","","13,509","","","54,497","","","26,052"],["Revenue under capitation arrangements","30,131","","","30,167","","","60,544","","","62,217"],["Total service revenue","$","622,720","","","$","498,230","","","$","1,198,351","","","$","969,629"]] [[/GREPCENT_TABLE]] Our revenue is not always consistent across each quarter. We generally experience the lowest volumes of procedures and the lowest level of revenue during the first quarter of each year. This is primarily the result of two factors. First, our volumes and revenue are typically impacted by winter weather conditions in our northeastern operations. It is common for snowstorms and other inclement weather to result in patient appointment cancellations and, in some cases, imaging center closures. Second, in recent years, we have observed greater participation in high deductible health plans by patients. Because these deductibles reset in January for most of these patients, a patient's out-of-pocket cost for a given procedure is generally highest during the first quarter and declines over the course of the year as the deductible is satisfied. As a significant portion of our outpatient imaging procedures are elective or schedulable, we have observed that patients defer these procedures to later quarters. Imaging Centers Acquisitions During the six months ended June 30, 2026, we completed the acquisition of certain assets of entities which engage directly in the practice of radiology or in associated businesses for an aggregate consideration of $86.0 million. These acquisitions include: Regional Radiology Center: 13 imaging centers in Florida; Northwest Radiology Network PC: 6 imaging centers in Indiana; and Intermountain Medical Imaging: 5 Centers in Idaho See Note 4, Business Combinations and Related Activity, in the notes accompanying our financial statements in this report for additional information, including the fair value determination of the acquired assets and assumed liabilities, associated with these acquisitions. 35 Table of Contents Joint Venture Activity At June 30, 2026, 157 of our imaging centers were operating as joint ventures with hospital and health system partners. On behalf of the joint ventures, we manage the day-to-day operations and perform most management and support services in exchange for a management fee. We charged management service fees from the centers underlying these joint ventures of approximately $7.9 million and $6.5 million for the three months ended June 30, 2026 and 2025, respectively, and $15.3 million and $12.6 million for the six months ended June 30, 2026 and 2025, respectively. For information on our investment in unconsolidated joint ventures, key balance sheet data and income statement data for the unconsolidated joint ventures, see Note 2, Significant Accounting Policies – Investment in Joint Ventures in the notes accompanying our financial statements included in this report. Critical Accounting Policies The SEC defines critical accounting estimates as those that (a) are most important to the portrayal of a company’s financial condition and results of operations and (b) require management’s most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 , Significant Accounting Policies, in the notes accompanying our financial statements included in this report and in our Annual Report, we discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management’s judgments and estimates are described below. Use of Estimates The financial statements included in this report were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements, our disclosure of contingent assets and liabilities at the dates of the financial statements, and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates. Revenues Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts of which our performance obligations are to provide diagnostic services to the patients. Revenue is recorded during the period our obligations to provide diagnostic services are satisfied, which is generally over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (in cases of Medicare and Medicaid) or negotiated with (in cases of managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related pa [Excerpt truncated for page length; source filing is linked above.] ## Latest 10-K MD&A (excerpt) Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/790526/000162828026013337/rdnt-20251231.htm Complete FY 2025 MD&A: /company/RDNT/mda/fy2025/ Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture. Confidence: high Filing date: 2026-03-02 Report date: 2025-12-31 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand the results of operations and financial condition of RadNet, Inc. The MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes included in this annual report on Form 10-K. Overview We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2025, we operated directly or indirectly through hospital and health system joint ventures, 418 centers located in Arizona, California, Delaware, Florida, Maryland, Virginia, New Jersey, New York, and Texas. Internationally, our subsidiary, The HLH Imaging Group Limited fka Heart & Lung Imaging Limited, provides teleradiology services for remote interpretation of images on behalf of providers within the framework of the United Kingdom's National Health Service. Our operations comprise two segments for financial reporting purposes for this reporting period, Imaging Centers and Digital Health. For further financial information about these segments, see Note 5, Segment Reporting, in the notes accompanying our consolidated financial statements included in this report. Our imaging centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. In addition to our imaging business, we established a Digital Health business segment during our 2024 fiscal year, which combines our former AI businesses with our eRad, Inc. business. Our Digital Health segment develops and delivers AI-powered health informatics solutions to improve quality, efficiency, and diagnostic outcomes in diagnostic imaging and radiology. We are using AI to develop solutions to assist radiologists and other clinicians in interpreting images and improving radiologist efficiency and patient care. The portfolio of AI and software solutions is anchored by Enterprise Operations solutions (traditionally knowns as RIS), Enterprise Imaging solutions (traditionally known as PACS), and Clinical AI solutions, enabled by the DeepHealth OS, a cloud-native operating system that connects critical aspects of the radiology service line from scheduling and patient preparation to technologist workflow to interpretation and referral management. Our Clinical AI solutions currently cover the fields of diagnosis and screening in the domain of breast, prostate, lung, thyroid, and brain. Across our portfolio of AI solutions, we have 22 FDA clearances and 15 CE marks. Our Digital Health segment provides these solutions to RadNet and to over 2000 customers in the U.S. and outside of the U.S. As part of our continued strategic expansion in Digital Health, we recently completed three acquisitions: iCAD, Inc., an AI-powered breast health solutions company; See-Mode Technologies, which enhances ultrasound-based diagnostics through artificial intelligence; and CIMAR (UK) Limited, which provides cloud-based medical image storage, PACS, and AI-enabled imaging workflow solutions. We are currently integrating these businesses into our Digital Health segment The following table presents the total number of imaging centers in operation at year end, including both consolidated and non-consolidated centers, and our consolidated revenues for the years ended December 31, 2025, 2024 and 2023. Revenue from non-consolidated centers is not included in consolidated revenues.  [[GREPCENT_TABLE]] [["","Years Ended December 31,"],["","2025","","2024","","2023"],["Centers in operation","418","","","398","","","366"],["Total consolidated revenue","$","2,040","","","$","1,830","","","$","1,617"]] [[/GREPCENT_TABLE]] Our revenue is derived from a diverse mix of payors, including private payors and commercial insurance companies, managed care capitated payors, and government payors such as Medicare and Medicaid. We believe our payor diversity mitigates our exposure to possible unfavorable reimbursement trends within any one payor class. Our total revenue for the years ended December 31, 2025, 2024 and 2023 is summarized in the following table (in thousands): 36 [[GREPCENT_TABLE]] [["In Thousands","2025","","2024","","2023"],["Commercial insurance","$","1,130,114","","","$","1,018,327","","","$","879,792"],["Medicare","476,987","","","410,072","","","356,506"],["Medicaid","51,736","","","44,736","","","42,302"],["Workers' compensation/personal injury","44,700","","","43,666","","","46,406"],["Other payors","118,599","","","104,888","","","87,675"],["Management fee revenue","27,516","","","24,676","","","17,936"],["Other revenue","65,021","","","46,724","","","32,580"],["Revenue under capitation arrangements","125,537","","","136,575","","","153,433"],["Total revenue","$","2,040,210","","","$","1,829,664","","","$","1,616,630"]] [[/GREPCENT_TABLE]]  Our revenue is not always consistent across each quarter. We generally experience the lowest volumes of procedures and the lowest level of revenue during the first quarter of each year. This is primarily the result of two factors. First, our volumes and revenue are typically impacted by winter weather conditions in our northeastern operations. It is common for snowstorms and other inclement weather to result in patient appointment cancellations and, in some cases, imaging center closures. Second, in recent years, we have observed greater participation in high deductible health plans by patients. As these high deductibles reset in January for most of these patients, we have observed that patients utilize medical services less during the first quarter, when securing medical care will result in significant out-of-pocket expenditures. Acquisitions, Equity Investments and Joint Venture Activity The following discussion summarizes certain details concerning our acquisition or disposition of centers, our equity investments, and our joint venture transactions. See Note 4, Business Combinations and Related Activity and Note 2, Summary of Significant Accounting Policies, in the notes accompanying our consolidated financial statements included in this report for further information. Acquisitions Imaging Center Segment Radiology Imaging Center Asset Acquisitions: During the years ended 2025 and 2024, we completed the acquisition of certain assets of the following entities, which engage directly in the practice of radiology or associated businesses. The primary reason for these acquisitions was to strengthen our presence in many of our geographic markets. These acquisitions are reported as part of our Imaging Center segment. We made a fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands): 2025: 37 [[GREPCENT_TABLE]] [["Entity","Date Acquired","Total Consideration","Property & Equipment","Right of Use Assets","Goodwill","Intangible Assets","Other Assets","Right of Use Liabilities","Finance lease"],["HALO Centers LLC","1/2/2025","$","4,200","","587","","3,238","","3,563","","50","","\u2014","","(3,238)","","\u2014"],["Hillcroft Medical Clinic","3/7/2025","$","734","","278","","\u2014","","406","","50","","\u2014","","\u2014","","\u2014"],["North County Radiology Oceanside LLC","4/1/2025","$","1,702","","238","","599","","1,307","","150","","7","","(599)","","\u2014"],["Faculty Physicians and Surgeons of LLUSM (Palm Imaging)","5/1/2025","$","1,400","","648","","\u2014","","702","","50","","\u2014","","\u2014","","\u2014"],["California MSK MSO, LLC (OSS Burbank)","5/1/2025","$","500","","330","","\u2014","","70","","100","","\u2014","","\u2014","","\u2014"],["HALO Centers LLC (Indian Wells)","5/1/2025","$","7,850","","1,714","","2,439","","6,072","","50","","15","","(2,439)","","\u2014"],["Kolb Radiology P.C.","7/1/2025","$","26,659","","6,887","","5,355","","22,396","","79","","155","","(6,125)","","(2,088)"],["Schonholz and Drossman, LLP","9/1/2025","$","30,101","","2,921","","5,566","","26,790","","295","","95","","(5,566)","","\u2014"],["Laser Assets, Inc.*","11/1/2025","$","29,058","","7,145","","4,529","","22,170","","134","","(32)","","(4,889)","","\u2014"],["Woodburn Nuclear Medicine, Ltd.*","11/1/2025","$","29,705","","1,658","","4,292","","27,902","","1,105","","\u2014","","(5,252)","","\u2014"],["River Radiology, PLLC*","11/3/2025","$","1,200","","798","","1,908","","244","","150","","8","","(1,908)","","\u2014"],["Total","","133,109","23,204","27,925","111,622","2,213","248","(30,015)","(2,088)"]] [[/GREPCENT_TABLE]] *Fair Value Determination is preliminary and subject to change 2024: 38 [[GREPCENT_TABLE]] [["Entity","Date Acquired","Total Purchase Consideration","Property & Equipment","Right of Use Assets","Goodwill","Intangible Assets","Other","Right of Use Liabilities","Notes payable and other liabilities"],["Antelope Valley Outpatient Imaging","2/1/2024","3,530","","2,793","","563","","687","","50","","\u2014","","(563)","","\u2014"],["Grossman Imaging Center of CMH, LLC","3/31/2024","10,343","1,717","6,304","8,500","280","56","(6,514)","\u2014"],["Providence Health System - Southern California","3/31/2024","7,369","1,378","3,441","5,991","\u2014","\u2014","(3,441)","\u2014"],["Houston Medical Imaging, LLC","4/1/2024","22,703","15,826","7,929","11,584","1,660","90","(8,089)","(6,297)"],["U.S. Imaging, Inc.","6/1/2024","4,200","4,025","5,597","\u2014","175","\u2014","(5,597)","\u2014"],["Global Imaging LLP","9/1/2024","2,900","1,266","\u2014","1,584","50","\u2014","\u2014","\u2014"],["Stanislaus Surgical Hospital, LLC","9/16/2024","3,000","503","1,468","2,382","100","15","(1,468)","\u2014"],["Pink Perception, LLC","10/7/2024","4,000","494","407","3,306","200","\u2014","(407)","\u2014"],["AV Imaging PLLC","11/1/2024","1,000","287","\u2014","663","50","\u2014","\u2014","\u2014"],["Total","","$","59,045","","$","28,289","","$","25,709","","$","34,697","","$","2,565","","$","161","","$","(26,079)","","$","(6,297)"]] [[/GREPCENT_TABLE]] Digital Health Segment See-Mode Technologies On June 2, 2025, through our wholly owned subsidiary DH AI International Holdings, B.V, we acquired all of the equity interest in See-Mode Technologies (“See-Mode”), a medical technology company focused on using artificial intelligence to enhance ultrasound-based diagnostics. See-Mode’s operations are included in our Digital Health segment for reporting purposes. The transaction was accounted for as the acquisition of a business with a total purchase consideration of approximately of $28.9 million, including: (i) cash of $17.9 million, (ii) a holdback of $2.0 million cash to be released 18 months after acquisition, and (iii) contingent consideration with a fair value of $9.0 million related to three performance milestones payable 50% in cash and 50% in shares of our common stock. We recorded $0.2 million in other net assets, $5.5 million in developed technology, $5.4 million in IPR&D, $20.0 million in goodwill, and $2.2 million in deferred tax liabilities in connection with this transaction. In performing the purchase price allocation, we considered, among other factors, the intended future use of the acquired assets, the historical financial performance, and estimates of the future performance of the See-Mode business. iCAD, Inc. On July 17, 2025, we completed the acquisition of all of the outstanding equity interests of iCAD, Inc. (“iCAD”), a global leader in AI-powered breast health solutions. The acquisition integrates iCAD’s commercial, technology, and regulatory capabilities with those of DeepHealth, our wholly owned subsidiary within the Digital Health segment. The transaction strengthens DeepHealth’s position as an industry leader in AI-enabled breast canc [Excerpt truncated for page length; the complete text is on the linked full-MD&A page.] Read the full FY 2025 MD&A: /company/RDNT/mda/fy2025/ All MD&A years: /company/RDNT/mda/ ## MD&A history Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page. - [FY 2024 MD&A](/company/RDNT/mda/fy2024/): filed 2025-03-03; accession 0001628280-25-009481 (https://www.sec.gov/Archives/edgar/data/790526/000162828025009481/rdnt-20241231.htm) - [FY 2023 MD&A](/company/RDNT/mda/fy2023/): filed 2024-02-29; accession 0001628280-24-008035 (https://www.sec.gov/Archives/edgar/data/790526/000162828024008035/rdnt-20231231.htm) - [FY 2022 MD&A](/company/RDNT/mda/fy2022/): filed 2023-03-01; accession 0000790526-23-000003 (https://www.sec.gov/Archives/edgar/data/790526/000079052623000003/rdnt-20221231.htm) - [FY 2021 MD&A](/company/RDNT/mda/fy2021/): filed 2022-03-01; accession 0000790526-22-000006 (https://www.sec.gov/Archives/edgar/data/790526/000079052622000006/rdnt-20211231.htm) ## Macro cross-references Indicators mapped to this company's SIC classification (industry 8071 Services-Medical Laboratories) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim. - [PCE](/indicator/PCE/): Personal Consumption Expenditures - [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product - [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm - [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private - [UNRATE](/indicator/UNRATE/): Unemployment Rate - [DSPIC96](/indicator/DSPIC96/): Real Disposable Personal Income Macro-to-micro threads including this sector: [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/). All macro indicators: /indicators/ ## For LLMs & downloads Markdown twin: /company/RDNT.md · JSON record: /company/RDNT.json · verified financials: /company/RDNT/financials.json / /company/RDNT/financials.csv · machine TOC for the whole site: /llms.txt